Precision medicine for metastatic breast cancer—limitations and solutions
暂无分享,去创建一个
S. Loi | C. Lefebvre | S. Michiels | F. André | H. Bonnefoi | M. Arnedos | C. Vicier
[1] Setia Pramana,et al. Integration of somatic mutation, expression and functional data reveals potential driver genes predictive of breast cancer survival , 2015, Bioinform..
[2] E. Winer,et al. Abstract CT231: A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with estrogen receptor+ HER2-, advanced/metastatic breast cancer , 2015 .
[3] C. Desmedt,et al. Predicting Anthracycline Benefit: TOP2A and CEP17-Not Only but Also. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] A. Ryan,et al. ATM and ATR as therapeutic targets in cancer. , 2015, Pharmacology & therapeutics.
[5] S. Gabriel,et al. Abstract PD3-5: Whole exome sequencing (WES) of HER2+ metastatic breast cancer (MBC) from patients with or without prior trastuzumab (T): A correlative analysis of TBCRC003 , 2015 .
[6] E. Winer,et al. Abstract PD5-5: Phase I study of the PI3Kα inhibitor BYL719 plus fulvestrant in patients withPIK3CA-altered and wild type ER+/HER2- locally advanced or metastatic breast cancer , 2015 .
[7] L. Pusztai,et al. Abstract S1-09: A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer , 2015 .
[8] Michael P. Schroeder,et al. In silico prescription of anticancer drugs to cohorts of 28 tumor types reveals targeting opportunities. , 2015, Cancer cell.
[9] C. Massard. O3.7Enriching phase I trials with molecular alterations: Interim analysis of 708 patients enrolled in the MOSCATO 01 , 2015 .
[10] H Abe,et al. Emergence of resistant variants detected by ultra‐deep sequencing after asunaprevir and daclatasvir combination therapy in patients infected with hepatitis C virus genotype 1 , 2015, Journal of viral hepatitis.
[11] Ayala Hubert,et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] Sohrab P. Shah,et al. Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution , 2014, Nature.
[13] J. Baselga,et al. Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] R. Paules,et al. Depletion of ATR selectively sensitizes ATM-deficient human mammary epithelial cells to ionizing radiation and DNA-damaging agents , 2014, Cell cycle.
[15] S. Loibl,et al. Does toxicity predict efficacy? Insight into the mechanism of action of lapatinib. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] R. Emerson,et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.
[17] Obi L. Griffith,et al. Convergent loss of PTEN leads to clinical resistance to a PI3Kα inhibitor , 2014, Nature.
[18] C Sotiriou,et al. The AURORA initiative for metastatic breast cancer , 2014, British Journal of Cancer.
[19] M. Berger,et al. Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[20] S. Loi,et al. 351OGENOMIC AND IMMUNE CHARACTERIZATION OF METASTATIC BREAST CANCER (MBC): AND ANCILLARY STUDY OF THE SAFIR01 & MOSCATO TRIALS. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[21] M. Kris,et al. LBA39_PRNERATINIB (N) WITH OR WITHOUT TEMSIROLIMUS (TEM) IN PATIENTS (PTS) WITH NON-SMALL CELL LUNG CANCER (NSCLC) CARRYING HER2 SOMATIC MUTATIONS: AN INTERNATIONAL RANDOMIZED PHASE II STUDY , 2014 .
[22] Sridhar Ramaswamy,et al. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility , 2014, Science.
[23] N. Navin,et al. Clonal Evolution in Breast Cancer Revealed by Single Nucleus Genome Sequencing , 2014, Nature.
[24] A. Schneeweiss,et al. Evaluating the predictive value of biomarkers for efficacy outcomes in response to pertuzumab- and trastuzumab-based therapy: an exploratory analysis of the TRYPHAENA study , 2014, Breast Cancer Research.
[25] S. Henderson,et al. APOBEC-mediated cytosine deamination links PIK3CA helical domain mutations to human papillomavirus-driven tumor development. , 2014, Cell reports.
[26] A. Tutt,et al. Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers , 2014, Breast Cancer Research.
[27] M. Zucchetti,et al. Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[28] J. Blay,et al. VE-BASKET, a first-in-kind, phase II, histology-independent "basket" study of vemurafenib (VEM) in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m). , 2014 .
[29] C. Isaacs,et al. Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. , 2014, The Lancet. Oncology.
[30] A. D. Van den Abbeele,et al. Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] D. Erdmann,et al. Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials , 2014, Molecular Cancer Therapeutics.
[32] Thomas Bachelot,et al. Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER). , 2014, The Lancet. Oncology.
[33] M. Dowsett,et al. Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in estrogen receptor-positive breast cancer. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[34] John M S Bartlett,et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. , 2014, Archives of pathology & laboratory medicine.
[35] Adam Kiezun,et al. Whole-exome sequencing and clinical interpretation of FFPE tumor samples to guide precision cancer medicine , 2013, Nature Medicine.
[36] David Chen,et al. ESR1 ligand binding domain mutations in hormone-resistant breast cancer , 2013, Nature Genetics.
[37] Javed Siddiqui,et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer , 2013, Nature Genetics.
[38] N. Rosen,et al. Tumor adaptation and resistance to RAF inhibitors , 2013, Nature Medicine.
[39] Benjamin J. Raphael,et al. Mutational landscape and significance across 12 major cancer types , 2013, Nature.
[40] Alan Ashworth,et al. Mechanisms of resistance to therapies targeting BRCA-mutant cancers , 2013, Nature Medicine.
[41] Mark J. Ratain,et al. Tumour heterogeneity in the clinic , 2013, Nature.
[42] Michael P. Schroeder,et al. IntOGen-mutations identifies cancer drivers across tumor types , 2013, Nature Methods.
[43] X. Hua,et al. DrGaP: a powerful tool for identifying driver genes and pathways in cancer sequencing studies. , 2013, American journal of human genetics.
[44] David T. W. Jones,et al. Signatures of mutational processes in human cancer , 2013, Nature.
[45] R. Salunga,et al. Analysis of the effect of various decalcification agents on the quantity and quality of nucleic acid (DNA and RNA) recovered from bone biopsies. , 2013, Annals of diagnostic pathology.
[46] Jinglong Wang,et al. Dual Inhibition of PI3K and mTOR Mitigates Compensatory AKT Activation and Improves Tamoxifen Response in Breast Cancer , 2013, Molecular Cancer Research.
[47] G. Hortobagyi,et al. Correlation of molecular alterations with efficacy of everolimus in hormone receptor–positive, HER2-negative advanced breast cancer: Results from BOLERO-2. , 2013 .
[48] Thomas Bachelot,et al. Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer , 2013, Clinical Cancer Research.
[49] N. Rosenfeld,et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA , 2013, Nature.
[50] Carlos Caldas,et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. , 2013, The New England journal of medicine.
[51] Li Ding,et al. Activating HER2 mutations in HER2 gene amplification negative breast cancer. , 2013, Cancer discovery.
[52] John M. S. Bartlett,et al. PIK3CA Genotype and a PIK3CA Mutation-Related Gene Signature and Response to Everolimus and Letrozole in Estrogen Receptor Positive Breast Cancer , 2013, PloS one.
[53] M. Mathieu,et al. Array CGH and PIK3CA/AKT1 mutations to drive patients to specific targeted agents: a clinical experience in 108 patients with metastatic breast cancer. , 2012, European journal of cancer.
[54] Matthew B. Callaway,et al. MuSiC: Identifying mutational significance in cancer genomes , 2012, Genome research.
[55] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumors , 2012, Nature.
[56] H. Gómez,et al. A gene expression signature of MEK pathway activation to predict survival in triple-negative breast cancer. , 2012 .
[57] A. Børresen-Dale,et al. The landscape of cancer genes and mutational processes in breast cancer , 2012, Nature.
[58] L. Zitvogel,et al. Loss-of-function alleles of P2RX7 and TLR4 fail to affect the response to chemotherapy in non-small cell lung cancer , 2012, Oncoimmunology.
[59] Stefan Michiels,et al. Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[60] Irmtraud M. Meyer,et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers , 2012, Nature.
[61] S. Ramaswamy,et al. Systematic identification of genomic markers of drug sensitivity in cancer cells , 2012, Nature.
[62] Razelle Kurzrock,et al. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[63] Mark Clemons,et al. Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[64] Jordi Rodon,et al. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[65] J. Baselga,et al. A Phase I Pharmacokinetic and Pharmacodynamic Study of Dalotuzumab (MK-0646), an Anti-Insulin-like Growth Factor-1 Receptor Monoclonal Antibody, in Patients with Advanced Solid Tumors , 2011, Clinical Cancer Research.
[66] Edward S. Kim,et al. The BATTLE trial: personalizing therapy for lung cancer. , 2011, Cancer discovery.
[67] G. Getz,et al. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers , 2011, Genome Biology.
[68] D. Sabatini,et al. mTOR: from growth signal integration to cancer, diabetes and ageing , 2010, Nature Reviews Molecular Cell Biology.
[69] Young Lim Choi,et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. , 2010, The New England journal of medicine.
[70] Mark Robson,et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial , 2010, The Lancet.
[71] A. Tutt,et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial , 2010, The Lancet.
[72] Anthony Rhodes,et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. , 2010, Archives of pathology & laboratory medicine.
[73] M. Barbacid,et al. Cell cycle, CDKs and cancer: a changing paradigm , 2009, Nature Reviews Cancer.
[74] C. Sander,et al. Functional Copy-Number Alterations in Cancer , 2008, PloS one.
[75] L. Pusztai,et al. Expression patterns and predictive value of phosphorylated AKT in early-stage breast cancer. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[76] Gordon B Mills,et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. , 2006, Cancer research.
[77] M. Cronin,et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.
[78] R. Tibshirani,et al. Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[79] R. Tampé,et al. Immune escape of melanoma: first evidence of structural alterations in two distinct components of the MHC class I antigen processing pathway. , 2001, Cancer research.
[80] Osborne Ck,et al. Tamoxifen in the Treatment of Breast Cancer , 1998 .
[81] W. McGuire,et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.
[82] E. Jensen,et al. Estrogen-Receptor Interaction , 1973, Science.
[83] Xin Huang,et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. , 2015, The Lancet. Oncology.
[84] J. Wolchok,et al. Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma. , 2015, The New England journal of medicine.
[85] D. Spaeth,et al. Translational studies within the TAMRAD randomized GINECO trial: evidence for mTORC1 activation marker as a predictive factor for everolimus efficacy in advanced breast cancer. , 2015, Annals of Oncology.
[86] G. Prendergast. A perspective on cancer as an abortive autoimmune response to altered-self. , 2015, Cancer research.
[87] Dennis C. Friedrich,et al. Whole-exome sequencing and clinical interpretation of formalin-fixed , paraffin-embedded tumor samples to guide precision cancer medicine , 2014 .
[88] G. Hortobagyi,et al. Correlation of molecular alterations with efficacy of everolimus in hormone-receptor-positive, HER2-negative advanced breast cancer: Results from BOLERO-2. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[89] Steven A. Roberts,et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes , 2013 .
[90] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumours , 2013 .
[91] Daniel F. Hayes,et al. Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer , 2013 .
[92] G. Hortobagyi,et al. Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[93] J. Thigpen. Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer , 2012 .
[94] K. Gelmon,et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial , 2011 .
[95] G. Hortobagyi,et al. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[96] Van,et al. A gene-expression signature as a predictor of survival in breast cancer. , 2002, The New England journal of medicine.
[97] C. Osborne,et al. Tamoxifen in the treatment of breast cancer. , 1998, The New England journal of medicine.